Greg Duncan is the Chief Executive Officer and Chairman of the Board of Directors of Virios Therapeutics. Previously, Mr. Duncan was President and Chief Executive Officer of Celtaxsys, Inc., a privately held biotech company focused on developing anti-inflammatory medicines for rare disease where he scaled the required capital to build out the organizational capability to advance both pre- clinical and clinical development candidates. Prior to Celtaxsys, he served as an Executive Committee member at Belgium based UCB, a specialty pharma entity developing and commercializing medicines for immunologic and central nervous system disorders. Before joining UCB, Mr. Duncan, while at Pfizer he held several executive U.S. and international appointments, including President of Pfizer’s $2B Latin America Operations and SVP of Marketing. His operational teams had accountability for the launches of many pharmaceutical brands including Lipitor, Zoloft, Viagra, Celebrex, Aricept, Lyrica, Cimzia, Zithromax (ZPack), Diflucan, Sutent, Rebif and Vimpat. Mr. Duncan has served as director for Biotie Therapeutics, the American Psychiatric Foundation, Bio International Organization (BIO), Southeast BIO (SEBIO and the Georgia Bio industry association groups. Greg holds a master’s degree in business administration from Emory University in Atlanta, GA, and a bachelor’s degree in economics from the State University of New York in Albany, NY.
What is Gregory Scott Duncan's net worth?
The estimated net worth of Gregory Scott Duncan is at least $25,472.46 as of August 17th, 2023. Mr. Duncan owns 57,461 shares of Virios Therapeutics stock worth more than $25,472 as of April 18th. This net worth evaluation does not reflect any other assets that Mr. Duncan may own. Additionally, Mr. Duncan receives a salary of $559,590.00 as CEO at Virios Therapeutics. Learn More about Gregory Scott Duncan's net worth.
How old is Gregory Scott Duncan?
What is Gregory Scott Duncan's salary?
How do I contact Gregory Scott Duncan?
Has Gregory Scott Duncan been buying or selling shares of Virios Therapeutics?
Gregory Scott Duncan has not been actively trading shares of Virios Therapeutics within the last three months. Most recently, on Thursday, August 17th, Gregory Scott Duncan bought 25,000 shares of Virios Therapeutics stock. The stock was acquired at an average cost of $1.25 per share, with a total value of $31,250.00. Following the completion of the transaction, the chief executive officer now directly owns 57,461 shares of the company's stock, valued at $71,826.25. Learn More on Gregory Scott Duncan's trading history.
Who are Virios Therapeutics' active insiders?
Are insiders buying or selling shares of Virios Therapeutics?
In the last twelve months, Virios Therapeutics insiders bought shares 2 times. They purchased a total of 40,335 shares worth more than $51,185.50. The most recent insider tranaction occured on August, 21st when Director William Pridgen bought 15,335 shares worth more than $19,935.50. Insiders at Virios Therapeutics own 11.7% of the company.
Learn More about insider trades at Virios Therapeutics. Information on this page was last updated on 8/21/2023.
